A look back at #SITC26, where our scientists presented new preclinical research on our novel PD-1 x VEGF x IL-7 multispecific immunocytokine.
The research explores an innovative approach to delivering IL-7 to PD-1-positive T cells, designed to preferentially activate anti-tumor T cells while limiting activity on bystander T cells. By advancing from PD-1 bispecific to trispecific antibodies, this approach also aims to address some of the clinical limitations of current checkpoint inhibitor strategies.
Read the poster: https://t.co/435DyIrNyt
Today, we honor and remember those who have served on Remembrance Day in Canada and Veterans Day in the United States. Thank you to all veterans and active service members for your dedication and sacrifice.
Zymeworks will present preclinical research on multispecific programs and cytokine engineering programs at PEGS Europe, taking place November 16–19 in Lisbon, Portugal.
Our presentations will explore next-generation tumor-targeted masked cytokines, including conditionally active IL-12 and IL-7 x PD-1 x VEGF molecules, a multispecific approach to inflammatory disease, and a differentiated T cell engager platform.
We look forward to connecting with the protein engineering community in Lisbon – learn more about our presentations: https://t.co/YLGMRgaEqc
#PEGSEurope #antibodyengineering
Management today reported third quarter 2026 financial results, providing an update on our financial performance and business progress.
Read the press release: https://t.co/g76VbjuVhd
Zymeworks will participate in upcoming investor conferences this month, engaging with members of the investment community on our strategy and portfolio.
This week our schedule includes:
- November 11 – @Stifel Healthcare Conference
- November 12 – @Truist BioPharma Symposium
We’ll also participate in the @Jefferies London Healthcare Conference next week on November 17.
Visit our website for event details: https://t.co/3EAR823AkL
Tomorrow at the Society for Immunotherapy of Cancer Annual Meeting, our team will present new preclinical data on a novel approach to targeted IL-7 delivery.
The approach incorporates IL-7 into a multispecific antibody designed to deliver the cytokine to tumor-specific T cells, with engineering strategies intended to limit activity on bystander T cells.
Presentation: Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
Abstract: 810
Date: Saturday, November 7
Location: PCC-North Building, Lower Level, Exhibition Halls 4–5–6
Learn more: https://t.co/slwHHkVGsx
#SITC2026
Zymeworks will be presenting at the 2026 American Society of Hematology Annual Meeting, sharing preclinical data on ZW1953, a new CD3 multispecific T cell engager designed to target FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation for AML.
Learn more: https://t.co/uZsoGLUDRX
#ASH26
Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer.
The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer.
Read the key data highlights here: https://t.co/yDVi8SDDUY
#OvarianCancer #ADC
Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager.
Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales.
Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization.
The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success.
Read the full announcement: https://t.co/rIAiQs7lRX
Zymeworks management will host a conference call on October 27 at 8:30 am ET.
#Oncology #RocheInnovation #pRED
We’re pleased to welcome Suzanne Monahan to Zymeworks as Senior Vice President, Commercial and General Manager, Theravance Biopharma.
Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in product launches, market access, strategic partnerships and respiratory markets.
In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: https://t.co/BZPwELGhm4
Zymeworks will report its third quarter 2026 financial results on November 9, and participate in several investor conferences throughout November, including the Wolfe Research, Stifel, Truist Securities, and Jefferies Healthcare Conferences.
We look forward to engaging with the investment community and sharing updates on our business and strategic priorities.
Read today’s announcement: https://t.co/NX92dDLRzL
Giving back to the communities where we live and work is an important part of who we are at Zymeworks.
This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on activities and community initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers.
We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success.
We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences.
At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer.
At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells.
At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering.
Learn more here: https://t.co/uzYwtNUht0
Today, on the National Day for Truth and Reconciliation and Orange Shirt Day, we pause to remember the children who never came home and honour Survivors, their families and communities.
We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect and build a better path forward together.
We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year.
Learn more: https://t.co/0k7p0jH4LD
#NationalDayforTruthandReconciliation #OrangeShirtDay
As Ovarian Cancer Awareness Month comes to a close, the need for awareness and support continues on.
For patients, caregivers and loved ones navigating a gynecologic cancer diagnosis, finding the right information and support can make a meaningful difference. Resources are available to help with everything from managing a diagnosis and finding support to navigating financial assistance and other challenges along the way.
Explore resources for patients and caregivers from the Ovarian Cancer Research Alliance: https://t.co/9gX82qYSUE
#OvarianCancer #CancerAwareness #Oncology
We’ve completed the acquisition of Theravance Biopharma, advancing our strategy to build a productive R&D company with a growing portfolio of revenue-generating assets and diversified, durable cash flows.
We’re also pleased to welcome Stuart Knight as EVP & CIO and Jesse Fecker, Ph.D., J.D., as VP, Intellectual Property.
Read the full announcement: https://t.co/5UmWQnEPCV
Join our conference call today at 8:30 am ET: https://t.co/FFBK6aktkb
Our Zymeworks team came together at Stanley Park this past weekend to run, walk and support @TerryFoxCanada's vision of a world without cancer. The Terry Fox Run continues to bring people together across Canada to raise funds for cancer research and carry forward Terry’s incredible legacy.
A huge congratulations to our team on an amazing fundraising effort, and thank you to everyone who ran, walked, donated, fundraised or cheered us on.
Well done, Team Zymeworks!
#TerryFoxRun #CancerResearch
Today, we announced the completion of our acquisition of Theravance Biopharma.
With the transaction now complete, Theravance Biopharma is officially part of Zymeworks, marking an important step in our strategy to build a diversified, revenue-generating biotechnology company combining innovative R&D with growing commercial and royalty-based cash flows.
We’ll host a conference call for investors and the general public on Monday, September 28 at 8:30 am ET to discuss the final transaction details.
Learn more and access the webcast: https://t.co/HOad5YISj7
We’re pleased to share that our FRα-targeting antibody-drug conjugate (#ADC) has been selected for a Rapid Oral Presentation at the 2026 @myESMO Congress in Madrid.
The presentation will feature new clinical results from our Phase 1 randomized dose optimization study in heavily pretreated patients with platinum-resistant ovarian cancer (PROC).
Title: Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer
Date/Time: Saturday, October 24 at 8:30–10:00 am CET
View this year's program: https://t.co/xeY4jIoEoq
We look forward to sharing these findings with the oncology community at #ESMO26!
#OvarianCancer #CancerResearch
September is Ovarian Awareness Month — an opportunity to recognize the patients and families affected by these cancers and highlight the importance of continued research and innovation.
We’re proud to share a recently published study from our scientists exploring the preclinical profile of our folate receptor alpha (FRα)-targeting antibody-drug conjugate. The research demonstrated promising anti-tumor activity across multiple tumor models, including ovarian and endometrial cancers, and provided insights into the differentiated properties of the antibody and payload.
Read the publication: https://t.co/bM1YqUyfNL
#OvarianCancer #ADC #CancerResearch